How to decide on the optimal duration of anticoagulatn therapy in carriers of the factor V Leiden mutation

Thromb Haemost. 2000 Nov;84(5):740-1.
No abstract available

Publication types

  • Comment

MeSH terms

  • Anticoagulants / administration & dosage*
  • Decision Making
  • Factor V / genetics*
  • Heterozygote
  • Humans
  • Mutation

Substances

  • Anticoagulants
  • factor V Leiden
  • Factor V